Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $58.0 million.

  • Monte Rosa Therapeutics' Non-Current Assets fell 915.72% to $58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.4 million, marking a year-over-year decrease of 941.72%. This contributed to the annual value of $61.3 million for FY2024, which is 925.48% down from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Non-Current Assets stood at $58.0 million, which was down 915.72% from $60.1 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Non-Current Assets ranged from a high of $70.5 million in Q2 2023 and a low of $58.0 million during Q3 2025
  • Moreover, its 3-year median value for Non-Current Assets was $66.2 million (2024), whereas its average is $64.9 million.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Non-Current Assets tumbled by 111.29% in 2024, and later plummeted by 1002.95% in 2025.
  • Monte Rosa Therapeutics' Non-Current Assets (Quarter) stood at $67.5 million in 2023, then dropped by 9.25% to $61.3 million in 2024, then decreased by 5.33% to $58.0 million in 2025.
  • Its Non-Current Assets stands at $58.0 million for Q3 2025, versus $60.1 million for Q2 2025 and $60.9 million for Q1 2025.